Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. et al
Case Number:
1:10-cv-01376
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 25, 2015
Eli Lilly Scores Win Over Teva In Alimta Patent Fight
An Indiana federal judge on Tuesday ruled that Teva Parenteral Medicines Inc.'s proposed labeling for a generic version of the cancer drug Alimta would cause physicians to infringe Eli Lilly & Co.'s vitamin-regimen patent.
-
July 23, 2015
Eli Lilly Slams 'Startling' Teva Brief In Alimta Patent Fight
Eli Lilly and Co. on Wednesday criticized as "startling" Teva Parenteral Medicines Inc.'s post-trial brief in a fight over whether Teva's labeling on a generic version of the cancer drug Alimta causes physicians to infringe Lilly's patent, saying Teva is asking the court to ignore the evidence from a May bench trial.
-
March 31, 2014
Eli Lilly Blocks Teva From Selling Generic Alimta
An Indiana federal judge on Monday upheld the validity of Eli Lilly & Co.'s patent for administering its blockbuster cancer treatment drug Alimta, finding that Teva Parenteral Medicines Inc.'s application for a generic version of the drug infringes the patent.